A widely available nutritional supplement derived from vitamin B5 may offer a promising new and accessible approach to managing and treating psoriasis, according to groundbreaking research conducted by a team of scientists in China. In their study, researchers discovered that pantethine—a familiar over-the-counter supplement—has the remarkable ability to calm specific immune cells heavily involved in autoimmune inflammation. This intervention successfully prevented psoriasis from developing in laboratory mice and meaningfully improved clinical symptoms during a small human trial.
The findings, which were published on October 27 in the Journal of Experimental Medicine (JEM), illuminate an unexpected and previously unrecognized biochemical connection between cholesterol production within the body and the regulation of the human immune system. By directly interfering with this specific metabolic pathway, pantethine may help reduce the excessive and damaging immune activity responsible for the hallmark flare-ups of psoriasis, while also opening doors for potential treatments in other autoimmune and inflammatory conditions.
How Overactive Immune Cells Contribute to Psoriasis
At the very center of this scientific discovery are dendritic cells, a specialized and vital class of immune cells that help organize, orchestrate, and direct the body’s natural defenses. These cells act primarily as biological coordinators, tasked with identifying potential foreign threats, assessing dangers, and directing other components of the immune system to mount an appropriate response.
Dendritic cells perform this critical role by capturing foreign substances, known as antigens, and presenting them directly to T cells, which are specialized immune cells designed to recognize and neutralize specific threats. In addition to antigen presentation, dendritic cells release powerful chemical signaling molecules that recruit additional immune cells to the site of an infection and trigger localized inflammation.
While these complex activities are entirely essential for fighting off pathogens and defending the body from harmful infections, severe problems can arise when dendritic cells become chronically or excessively active. Instead of helping protect the host, hyperactive dendritic cells can drive persistent, destructive inflammation and contribute significantly to chronic autoimmune diseases, most notably psoriasis—a condition characterized by painful, scaly, and inflamed patches of skin.
"Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression," says Wei-Na Zhang, a researcher at the State Key Laboratory of Biomedical Analysis in Beijing. "But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored."
Zhang led the extensive research alongside colleagues Qing Xia, Ai-Ling Li, and Tao Zhou, who are also based at the State Key Laboratory of Biomedical Analysis, as well as Cheng-Xin Li from The First Medical Center of Chinese PLA General Hospital in Beijing. Together, this collaborative team set out to investigate how cellular metabolism intersects with immune dysregulation in autoimmune diseases.
Scientists Discover a Hidden Link Between Cholesterol and Psoriasis
During their investigation, the research team identified unusually high levels of specific enzymes known as Vanins within the dendritic cells harvested from human patients suffering from psoriasis, alongside several other autoimmune conditions. These regulatory enzymes play a major role in controlling the processing of specific substances involved in foundational cellular metabolism.
When the scientists experimentally reduced Vanin levels within these cells, they observed an immediate and striking change: the dendritic cells became significantly less active and showed a markedly diminished capacity to stimulate T cells. Furthermore, when the researchers administered a specialized pharmacological drug designed to inhibit Vanin activity, it successfully prevented the development of psoriasis-like skin conditions in experimental animal models.
Further investigation into the biological pathways at play revealed why these particular enzymes might hold such profound influence over immune behavior.
Vanins function biochemically by converting pantethine into vitamin B5, an essential nutrient that human cells require to produce adequate energy and maintain normal metabolic functions. Pantethine itself is already widely manufactured, sold as a common nutritional supplement, and frequently utilized in clinical settings to help manage blood cholesterol levels because of its proven ability to reduce overall cholesterol synthesis in the body.
This metabolic connection is particularly fascinating because cholesterol does much more than simply circulate passively through the bloodstream to affect cardiovascular health. Cholesterol actively influences how individual immune cells behave and function. Previous scientific research has robustly demonstrated that elevated intracellular cholesterol can stimulate dendritic cell activity, while clinical data consistently shows that elevated blood cholesterol is a major risk factor for developing or worsening psoriasis.
The research team discovered that excessive Vanin activity actively depletes the amount of pantethine available inside dendritic cells. As these critical pantethine levels fall, intracellular cholesterol production ramps up, causing these immune cells to enter a state of hyperactivation that drives tissue inflammation.
When the scientists restored pantethine levels through direct supplementation, it effectively interrupted this destructive cascade. The supplement successfully reduced the abnormal accumulation of cholesterol within the dendritic cells and helped suppress the excessive immune activation that underpins chronic inflammation.
"We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the up-regulation of Vanins," Zhang explains.
Common Supplement Shows Promise in Human Psoriasis Trial
Encouraged by their robust laboratory findings and successful animal experiments, the researchers sought to determine whether pantethine might translate into tangible clinical benefits for human beings living with the chronic burdens of psoriasis.
To explore this possibility, the team designed and conducted a small, investigator-initiated clinical trial involving 24 human patients diagnosed with the condition. Throughout the duration of the study, all participants received a standard topical ointment containing a combination of calcipotriene and betamethasone, which is a conventional combination treatment routinely prescribed to help control active psoriasis symptoms. Calcipotriene is a synthetic vitamin D derivative that helps regulate excessive skin cell growth, while betamethasone is a potent corticosteroid utilized to reduce localized skin inflammation.
To test the hypothesis, half of the study participants were also given oral pantethine tablets alongside their prescribed topical regimen, allowing researchers to evaluate whether adding the common nutritional supplement could measurably improve the therapeutic outcomes of standard care.
After a treatment period of 12 weeks, the patients who received pantethine in conjunction with their prescribed ointment demonstrated significantly greater overall improvement in their psoriasis symptoms compared to those receiving the standard treatment alone. Notably, these therapeutic benefits were especially pronounced among study participants who presented with high blood cholesterol levels prior to the commencement of the trial.
These encouraging clinical findings strongly suggest that pantethine could potentially serve as a valuable, low-cost adjunctive treatment for psoriasis, particularly for patients whose underlying cholesterol metabolism may be actively contributing to their inflammatory skin symptoms.
However, because the trial included only a small cohort of 24 individuals, the researchers urge caution and emphasize that much larger, multi-center clinical studies will be absolutely necessary to definitively confirm the supplement’s widespread efficacy and safety profile. Furthermore, the human trial results do not definitively establish that the exact same biological and metabolic mechanisms observed in controlled laboratory experiments are solely responsible for the clinical improvements seen in the patients.
"Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation," Zhang notes. "Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell-mediated autoimmune diseases."
